The TABLET trial

The TABLET trial is an important research study which is looking at the role of thyroid antibodies in women with unexplained miscarriage.

The researchers are particularly interested in seeing whether a drug called Levothyroxine reduces the risk of miscarriage in women who have thyroid antibodies even though their thyroid hormones are in the normal range.

At 26 January 2016, the trial has now stopped recruiting.   A total of 952 women have been recruited to date and this is enough to show whether the treatment makes a difference or not.

The trial results are expected to be available in Spring 2018. Eighteen months may seem like a very long time to be waiting for the trial results.  The reason for this time-frame is that the team needs to follow up all the women taking part throughout their treatment and pregnancies, once they conceive (and sadly, some won’t).   We will bring you the results as soon as they are available.

We’ve kept information about the trial below for those who would like to know about it.


TABLET is a randomised, double-blind, placebo-controlled trial:

Randomised The women who take part will be given either the treatment drug (Levothyroxine) or a placebo – a dummy drug that has no active ingredients. A computer makes the selection so it’s completely random.

Double-blind The women in the study won’t be told whether they are taking the active medicine or the placebo – and neither will their doctors. So both are blinded to this information.

Placebo-controlled Half the women in the study will have the active medicine and half (the controlswill have the placebo.  The medicine that they receive will look exactly the same to them and their doctors, but a completely separate group will keep a record of which women have Levothyroxine and which have the placebo.

Who can take part?

The researchers have recruited women who:

  • are aged 16 – 40
  • hope to conceive in the next year
  • have had a previous miscarriage or are due to have fertility treatment
  • do not have known thyroid disease – and
  • are willing to be selected at random to have either the treatment or a placebo, without knowing which they are given.

Where is it taking place?

The following hospitals are taking part in the trial:

  • Arrowe Park Hospital, Wirral
  • Basildon Hospital
  • Birmingham Heartlands Hospital
  • Birmingham Women’s Hospital
  • Bradford Royal Infirmary
  • Burnley General Hospital
  • City Hospital, Birmingham
  • Colchester Hospital
  • Countess of Chester Hospital
  • Crosshouse Hospital, Ayrshire
  • Cumberland Infirmary
  • Derby Hospital
  • Derriford Hospital, Plymouth
  • Durham Hospital
  • Ealing Hospital, London
  • Fairfield General, Burnley
  • Frimley Park Hospital
  • Furness General Hospital, Cumbria
  • Guy’s Hospital, London
  • James Cook Hospital, Middlesbrough
  • Kings College Hospital, London
  • Liverpool Women’s Hospital
  • New Cross Hospital, Wolverhampton
  • Newham University Hospital
  • North Manchester General Hospital
  • Ormskirk Hospital
  • Princess Royal, Telford
  • Queen’s Medical Centre, Nottingham
  • Rochdale Hospital
  • Royal Bolton Hospital
  • Royal Bournemouth Hospital
  • Royal Cornwall Hospital
  • Royal Devon and Exeter Hospital
  • Royal London Hospital
  • Royal Oldham Hospital
  • Royal Shrewsbury Hospital
  • Royal United Hospital, Bath
  • Royal Victoria, Newcastle-upon-Tyne
  • St Bartholomew’s Hospital
  • St James’s Hospital, Leeds
  • St Mary’s Hospital, Manchester
  • St Mary’s Hospital, London
  • St Michael’s Hospital, Bristol
  • St Peter’s Hospital, Chertsey
  • St Thomas’s Hospital, London
  • University College Hospital, London
  • University Coventry and Warwickshire Hospitals
  • Warrington Hospital
  • Watford General Hospital
  • Whipps Cross Hospital
  • Wrightington Hospital

There is also information on the trial website.

If you would like more information, please contact the TABLET office at

If your questions are less medical/scientific and more about feelings or concerns, do contact us at or call us on 01924 200799.